Literature DB >> 31564175

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.

Kalle E Mattila1,2, Pia Vihinen1,2, Susan Ramadan1,2, Tanja Skyttä3,4, Leena Tiainen3,4, Meri-Sisko Vuoristo3,4, Kristiina Tyynelä-Korhonen5, Jussi Koivunen6, Laura Kohtamäki7, Siru Mäkelä7, Micaela Hernberg7.   

Abstract

Entities:  

Year:  2019        PMID： 31564175     DOI： 10.1080/0284186X.2019.1670862

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  2 in total

1.  Antitumor effect of Melaleuca alternifolia essential oil and its main component terpinen-4-ol in combination with target therapy in melanoma models.

Authors:  Marta Di Martile; Stefania Garzoli; Manuela Sabatino; Elisabetta Valentini; Simona D'Aguanno; Rino Ragno; Donatella Del Bufalo
Journal:  Cell Death Discov       Date:  2021-05-31

Review 2.  Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma.

Authors:  Paola Savoia; Elisa Zavattaro; Ottavio Cremona
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.